C/M CAPITAL PARTNERS, LP - 30 Jun 2025 SCHEDULE 13G/A Report for Biodexa Pharmaceuticals Plc Ordinary Shares, nominal value 0.000001 GBP per share (BDRX)

Filing manager
C/M CAPITAL PARTNERS, LP
Reporting owner
Cavalry Fund I LP
Security
Biodexa Pharmaceuticals Plc Ordinary Shares, nominal value 0.000001 GBP per share
Beneficially owned shares
0 shares
Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

0%

Beneficial ownership of this reported class.

Shares

0 shares

Shares beneficially owned as disclosed.

Event date

30 Jun 2025

Date tied to the ownership event or amendment.

Accepted by SEC

14 Nov 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership
0%
Subject security Names, identifiers, and filing context for this profile. 1 source field
Symbol
BDRX
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
SCHEDULE 13G/A
Accepted by SEC
14 Nov 2025, 16:18:12 UTC
Event date
30 Jun 2025
Source filing
View source filing

Key filing fact

C/M CAPITAL PARTNERS, LP disclosed 0% ownership in Biodexa Pharmaceuticals Plc Ordinary Shares, nominal value 0.000001 GBP per share (BDRX) on 30 Jun 2025.

Key facts

  • C/M CAPITAL PARTNERS, LP filed SCHEDULE 13G/A for Biodexa Pharmaceuticals Plc Ordinary Shares, nominal value 0.000001 GBP per share (BDRX).
  • Disclosed ownership: 0%.
  • Date of event: 30 Jun 2025.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Nov 2025, 16:18.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (8)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Cavalry Fund I LP 0% 0 0 0 /s/ Thomas Walsh By: Cavalry Fund I GP LLC, General Partner, By: Thomas Walsh, Manager
C/M CAPITAL PARTNERS, LP 0% 0 0 0 /s/ Thomas Walsh Thomas Walsh, Partner
Cavalry Investment Fund, LP 0% 0 0 0 /s/ Thomas Walsh By: Cavalry Fund GP, LLC, General Partner, By: Thomas Walsh, Managing Member
Cavalry Fund I Management LLC 0% 0 0 0 /s/ Thomas Walsh Thomas Walsh, Manager
Mercer Street Global Opportunity Fund, LLC 0% 0 0 0 /s/ Jonathan Juchno By: NFSO, LLC, its General Partner, By: Jonathan Juchno, Authorized Representative
Mercer Street Capital Partners, LLC 0% 0 0 0 /s/ Jonathan Juchno Jonathan Juchno, Authorized Representative
Thomas Walsh 0% 0 0 0 /s/ Thomas Walsh Thomas Walsh, Individually
Jonathan Juchno 0% 0 0 0 /s/ Jonathan Juchno Jonathan Juchno, Individually
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .